Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Market Perform at Leerink Partners

Leerink Partners lowered shares of Agios Pharmaceuticals (NASDAQ:AGIO) from an outperform rating to a market perform rating in a research report sent to investors on Friday, Marketbeat.com reports. They currently have $56.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $60.00.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a neutral rating in a report on Tuesday, June 4th. JPMorgan Chase & Co. reissued a neutral rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. StockNews.com lowered shares of Agios Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. Cantor Fitzgerald reissued an overweight rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and a consensus target price of $52.50.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock opened at $44.43 on Friday. The business has a fifty day simple moving average of $45.61 and a two-hundred day simple moving average of $39.92. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $53.28. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -7.03 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.51) EPS. As a group, equities analysts anticipate that Agios Pharmaceuticals will post -4.85 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of AGIO. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals in the second quarter valued at about $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $40,000. NEOS Investment Management LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $210,000. North Star Asset Management Inc. acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at approximately $216,000. Finally, XTX Topco Ltd bought a new position in shares of Agios Pharmaceuticals during the second quarter valued at $230,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.